S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14

Tyme Technologies (TYME) Stock Forecast, Price & News

+0.01 (+3.92%)
(As of 05/18/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
421,204 shs
Average Volume
840,192 shs
Market Capitalization
$45.62 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

Tyme Technologies logo

About Tyme Technologies

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.59 per share


Net Income
$-28.98 million
Pretax Margin




Free Float
Market Cap
$45.62 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.34 out of 5 stars

Medical Sector

1120th out of 1,426 stocks

Pharmaceutical Preparations Industry

557th out of 680 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

Are investors shorting Tyme Technologies?

Tyme Technologies saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,390,000 shares, a drop of 34.4% from the April 15th total of 2,120,000 shares. Based on an average daily trading volume, of 638,600 shares, the short-interest ratio is presently 2.2 days. Approximately 1.2% of the shares of the company are sold short.
View Tyme Technologies' Short Interest

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, June 9th 2022.
View our earnings forecast for Tyme Technologies

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) announced its earnings results on Monday, November, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03.
View Tyme Technologies' earnings history

Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the following people:
  • Mr. Richard Cunningham, CEO & Director (Age 51, Pay $355.97k)
  • Mr. Steven E. Hoffman, Co-Founder & Director (Age 59, Pay $819.66k) (LinkedIn Profile)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 58, Pay $645.52k)
  • Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 48, Pay $556.56k)
  • Mr. Frank L. Porfido, Chief Financial Officer (Age 58)
  • Dr. Jan Marie-Albert Van Tornout M.D., M.Sc., Acting Chief Medical Officer (Age 66)
What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Who are Tyme Technologies' major shareholders?

Tyme Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.25%), Renaissance Technologies LLC (0.73%), GSA Capital Partners LLP (0.34%), Kercheville Advisors LLC (0.06%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Diana F Cantor, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman, Tornout Jan M Van and Tornout Jan M Van.
View institutional ownership trends for Tyme Technologies

Which major investors are selling Tyme Technologies stock?

TYME stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Kercheville Advisors LLC, Simplex Trading LLC, HAP Trading LLC, and Cutler Group LP. Company insiders that have sold Tyme Technologies company stock in the last year include Diana F Cantor, Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies
or view top insider-selling stocks.

Which major investors are buying Tyme Technologies stock?

TYME stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, and Group One Trading L.P.. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, and Tornout Jan M Van.
View insider buying and selling activity for Tyme Technologies
or or view top insider-buying stocks.

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $0.26.

How much money does Tyme Technologies make?

Tyme Technologies has a market capitalization of $45.62 million. The company earns $-28.98 million in net income (profit) each year or ($0.140010) on an earnings per share basis.

How many employees does Tyme Technologies have?

Tyme Technologies employs 17 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at (212) 461-2315 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.